Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer's Sutent in a Phase III trialOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.